Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Case Western to study rEV-576 for myasthenia gravis

May 30, 2006

Enrollment completed in first phase III trial of PRX-00023 in GAD

May 30, 2006

Cannabinoid CB2 receptors as a target for anxiety and substance abuse

May 29, 2006

Recent patents describe novel agents for anxiety, depression, psychosis, etc.

May 29, 2006

EnVivo sets out plans for drug development progression

May 29, 2006

Pagoclone produces decrease in severity of stuttering

May 29, 2006

URB-597 has antidepressant activity in animal models

May 29, 2006

Quetiapine shows potential as monotherapy in bipolar depression

May 26, 2006

Three new mechanism-of-action studies begin for VNS Therapy

May 26, 2006

Newer antiepileptic drugs show potential in cyclic vomiting syndrome

May 26, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...